<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893162</url>
  </required_header>
  <id_info>
    <org_study_id>PROMEX</org_study_id>
    <nct_id>NCT03893162</nct_id>
  </id_info>
  <brief_title>Gut Feeling: Understanding the Mechanisms Underlying the Antidepressant Properties of Probiotics</brief_title>
  <acronym>PROMEX</acronym>
  <official_title>Gut Feeling: Understanding the Mechanisms Underlying the Antidepressant Properties of Probiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous research has suggested that probiotics can improve depressive symptoms in patients&#xD;
      with Major Depressive Disorder (MDD), particularly when used in addition to antidepressants.&#xD;
      The aim of this exploratory pilot study is to improve the investigator's understanding of the&#xD;
      mechanisms underlying these effects. This study will assess the effects of an 8-week&#xD;
      double-blind placebo-controlled probiotic intervention on the gut microbiome, inflammatory&#xD;
      marker levels, brain activity and neurotransmitter levels in patients with MDD and their&#xD;
      relationship to changes in mood. This study will also recruit a group of&#xD;
      demographically-matched healthy controls for gut microbiome comparison with the MDD group&#xD;
      (non-interventional).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gut microbiota in MDD</measure>
    <time_frame>baseline</time_frame>
    <description>species diversity and abundance at the level of organisational taxonomic units (OTUs) will be measured with 16S ribosomal RNA (rRNA) sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>differences in gut microbiota between MDD and healthy volunteers</measure>
    <time_frame>baseline</time_frame>
    <description>species diversity and abundance at the level of OTUs will be measured with 16SrRNA-based sequencing and compared between the two groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gut microbiota changes in MDD following probiotic intervention and their correlation to change in depressive symptoms</measure>
    <time_frame>change from baseline to week 8</time_frame>
    <description>species diversity and abundance at the level of OTUs will be measured with 16SrRNA-based sequencing and depressive symptoms will be measured with the Inventory of Depressive Symptomatology Self-Report (IDS-SR) and the Hamilton Depression Rating Scale (HAM-D17)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurotransmitters</measure>
    <time_frame>change from baseline to week 8</time_frame>
    <description>levels of glutamate and gamma-aminobutyric acid (GABA) will be measured with Magnetic Resonance Imaging (MRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood</measure>
    <time_frame>change from baseline to week 8</time_frame>
    <description>levels of tumor necrosis factor (TNF-a), interleukins IL-1Î², IL-6, IL-17, and C-reactive protein (CRP) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain activity</measure>
    <time_frame>change from baseline to week 8</time_frame>
    <description>measured with functional magnetic resonance imaging (fMRI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Multi-strain probiotic &quot;BioKult&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 capsules daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 capsules daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multi-strain probiotic</intervention_name>
    <description>The intervention in this study is a multi-strain probiotic which contains:&#xD;
Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.&#xD;
Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram.</description>
    <arm_group_label>Multi-strain probiotic &quot;BioKult&quot;</arm_group_label>
    <other_name>&quot;BioKult&quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Visually identical capsules in identical packaging containing no active bacteria.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for MDD participants:&#xD;
&#xD;
          -  aged 18-55;&#xD;
&#xD;
          -  currently in a depressive episode according to DSM-5 criteria, who are currently on&#xD;
             antidepressant treatment but remain symptomatic (HAM-D17 score &gt;13);&#xD;
&#xD;
          -  on stable treatment regimen of an approved treatment for at least 6 weeks;&#xD;
&#xD;
          -  non-smokers;&#xD;
&#xD;
          -  for participants willing to take part in the neuroimaging component: right-handed, no&#xD;
             contraindications, non-claustrophobic, weight &lt;126kg;&#xD;
&#xD;
        Exclusion criteria for MDD participants:&#xD;
&#xD;
          -  eating disorder, bipolar disorder, schizophrenia or psychotic symptoms;&#xD;
&#xD;
          -  substance dependence in the past year, except for caffeine;&#xD;
&#xD;
          -  active suicidal ideation;&#xD;
&#xD;
          -  use of probiotic supplements in the past 2 weeks, or regular use of a probiotic;&#xD;
&#xD;
          -  use of antibiotics in the past 12 weeks;&#xD;
&#xD;
          -  history of allergic reaction to any of the components of BioKult;&#xD;
&#xD;
          -  history of history of a systemic medical illness;&#xD;
&#xD;
          -  current presence of significant GI problems or disease or history of major GI surgery;&#xD;
&#xD;
          -  pregnancy or breastfeeding;&#xD;
&#xD;
          -  following a dietary regimen unrepresentative of the general population (e.g. fasting&#xD;
             or following a specific diet);&#xD;
&#xD;
          -  regular/current use of antacids, proton pump inhibitors, laxatives, antidiarrheals;&#xD;
&#xD;
        Inclusion criteria for Healthy Volunteers:&#xD;
&#xD;
          -  Aged 18-55;&#xD;
&#xD;
          -  No current or historic presence of depression, other psychiatric disorder or substance&#xD;
             dependence&#xD;
&#xD;
          -  No history of a systemic medical illness;&#xD;
&#xD;
          -  No family history of psychiatric disorder;&#xD;
&#xD;
          -  Non-smoker;&#xD;
&#xD;
          -  Not used probiotic supplements in the past 2 weeks, nor regular use of a probiotic;&#xD;
&#xD;
          -  Not used antibiotics in the past 12 weeks;&#xD;
&#xD;
          -  No current presence of gastrointestinal disease, or history of major GI surgery;&#xD;
&#xD;
          -  No reported regular/current use of antacids, proton pump inhibitors, laxatives,&#xD;
             antidiarrheals;&#xD;
&#xD;
          -  pregnancy or breastfeeding;&#xD;
&#xD;
          -  not currently following a dietary regimen or dietary restrictions unrepresentative of&#xD;
             the general population (e.g. fasting or following a specific diet);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M Stone, MBBS PhD FRCPsych</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Psychiatry Psychology and Neuroscience, King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Viktoriya Nikolova, BSc, MRes</last_name>
    <phone>020 3228 3057</phone>
    <email>viktoriya.nikolova@kcl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktoriya Nikolova</last_name>
      <phone>TBA</phone>
      <email>viktoriya.nikolova@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>James M Stone, MBBS PhD FRCPsych</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>depression</keyword>
  <keyword>microbiome</keyword>
  <keyword>bacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

